论文部分内容阅读
COMT参与雌激素的代谢过程.本实验室前期通过蛋白质组学及免疫蛋白质组学筛选得出,COMT可能是胰腺癌的一种候选生物标记物.本文旨在研究COMT在胰腺导管腺癌及非癌胰腺组织中的表达情况,并探讨COMT表达与临床病理参数的联系.通过RT-PCR及Western blot方法检测COMT在5株胰腺癌细胞株中的表达,利用免疫组学方法检测COMT在组织芯片及20例石蜡包埋临床胰腺标本中的表达.结果显示,COMT在胰腺癌细胞株AsPC-1,BxPC-3,MIAPaCa-2,Capan-1,SW1990及5组胰腺导管腺癌和其对应的非癌胰腺组织中均有表达.免疫组化结果显示,COMT在PDAC中的表达显著高于非癌胰腺组织,COMT的高表达与低级别T分期显著相关.因此,COMT可能是PDAC潜在的临床病理标记物.
COMT is involved in the metabolic process of estrogen.Our laboratory preliminarily selected COMT as a candidate biomarker for pancreatic cancer through proteomics and immuno proteomics screening.The purpose of this paper is to investigate the role of COMT in pancreatic ductal adenocarcinoma and non- The expression of COMT in 5 pancreatic cancer cell lines was detected by RT-PCR and Western blot, and the expression of COMT was detected by immunohistochemistry in tissue microarray And 20 cases of paraffin embedded clinical pancreatic specimens.The results showed that the expression of COMT in pancreatic ductal adenocarcinoma of pancreatic cancer cell lines AsPC-1, BxPC-3, MIAPaCa-2, Capan-1, SW1990 and 5 The results of immunohistochemistry showed that the expression of COMT in PDAC was significantly higher than that in non-cancerous pancreatic tissue, and the high expression of COMT was significantly associated with low-grade T stage.Therefore, COMT may be a potential clinical Pathological markers.